Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial–a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial

Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial–a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial

<p><strong>Background:</strong> Chronic kidney disease (CKD) is common and increasing in prevalence. Cardiovascular disease (CVD) is a major cause of morbidity and death in CKD, though of a different phenotype to the general CVD population. Few therapies have proved effective in mo...

Full description

Bibliographic Details
Main Authors: Hill, NR, Lasserson, D, Thompson, B, Perera-Salazar, R, Wolstenholme, J, Bower, P, Blakeman, T, Fitzmaurice, D, Little, P, Feder, G, Qureshi, N, Taal, M, Townend, J, Ferro, C, McManus, R, Hobbs, FDR
Format: Journal article
Language:English
Published: BioMed Central 2014
Subjects:
cardiovascular disease
nephrology
disease prevention

Similar Items